To address healthcare challenges across the world, we unite a biotech spirit with the strength of a successful pharmaceutical business. The result is a biopharmaceutical company combining science, passion, and expertise to improve health and healthcare in new ways. Making a remarkable impact in people's lives is more than our promise. It's our purpose.



Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth.


Agenus is an immuno-oncology company driven by innovation. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.


Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.

Bayer is a world-class innovation company with a 150-year history. Our scientific successes are intended to help improve people’s lives. At the same time, our innovations form the basis for sustainable and profitable business activity and are the key to maintaining or achieving leadership positions in all of our markets.


Our products are helping to address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources.

·         We are improving people’s quality of life by preventing, alleviating or curing diseases.

·         We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based
raw materials.

·         Our high-tech polymer materials are making significant contributions in areas such as energy and resource efficiency for mobility, construction and home living.

In line with our mission “Bayer: Science For A Better Life,” we aim to improve people’s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.

Bristol-Myers Squibb is the world leader in providing life-saving and life-extending therapies for people with cancer. All of the company's considerable resources and expertise in oncology are marshaled toward the single goal of providing safer and more effective anticancer medicines. The mission of Bristol-Myers Squibb Oncology is to extend and enhance the lives of people living with cancer.

Caris Life Sciences® develops and delivers innovative molecular diagnostic, prognostic and theranostic services.  Molecular Intelligence™, from Caris Life Sciences, is the world’s foremost evidence-based tumor profiling service designed to provide oncologists with the most relevant, clinically-actionable and individualized treatment information to personalize cancer care for all solid tumors. The company’s Carisome™ platform, currently under development, is a proprietary, blood-based testing technology for diagnosis, prognosis and theranosis of cancer and other complex diseases.

Celgene Corporation (Nasdaq:CELG) is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers and other serious conditions into chronic, manageable diseases through innovative therapies. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide.

Clovis is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.


Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant  unmet medical needs. Genentech manufactures and commercializes several major oncology drugs include Herceptin, Rituxan, Avastin and Tarceva. 

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.



ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla®. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at

For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative firsts, Janssen Biotech, Inc. pursues patient-focused solutions in the therapeutic areas of immunology and oncology. With the same unwavering passion for new challenges, we dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.  Rooted in rich scientific collaborations and community-based relationships, we have access to some of the top minds in science today, allowing us to advance the treatment of patients through our innovative medicines. Our discoveries lead us not only to new treatments, but also to new ways to empower patients and expand their access to quality care.  For more about Janssen Biotech, Inc.

Eli Lilly and Company is a leading innovation-driven corporation and is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

Lilly Oncology is committed to providing comprehensive healthcare solutions – answers that matter – for oncologists and cancer patients around the world through the discovery and development of breakthrough cancer medicines.



Novartis Oncology is dedicated to innovative approaches, practical solutions and valuable medical therapies that satisfy the current and emerging needs of the Oncology community.  Current marketed products in oncology are Gleevec™, Femara™, Zometa™, and Sandostatin™

Palti’s initial research from his basement laboratory has evolved to become an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.

We launched Optune® – our Tumor Treating Fields delivery system for glioblastoma (GBM) – in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, we received U.S. Food and Drug Administration (FDA) approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide.  We actively market for that indication in the United States, Germany and Switzerland.

The science of Tumor Treating Fields has the potential to extend beyond GBM. We have five ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. We presented our phase 2 pilot data in pancreatic and ovarian cancers at our research and development day on Dec. 12, 2016. In 2016, we began our phase 3 pivotal trial in brain metastases originating from NSCLC. In 2017, we started our phase 3 pivotal trial in NSCLC. Internationally, more than 20 institutions are studying the effects of Tumor Treating Fields in cancer treatment.

Our company began with a patient-forward approach that continues to drive our mission today. With more than 15 years of research and many significant milestones, we have established ourselves as an innovator in oncology dedicated to improving the lives of cancer patients.

Pfizer is a research-based global pharmaceutical company dedicated to helping people live longer, healthier lives. It invests more than $2 billion annually in research, searching for treatments and cures for cancer, osteoporosis, diabetes, Alzheimer's disease, arthritis, heart disease, sexual dysfunction, and a wide variety of other diseases. Pfizer is also a leader in animal health, offering medicines for companion and farm animals, and in consumer health care products.


We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.



TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapies.



Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is currently being studied in a Phase 3 pivotal trial for Recurrent Glioblastoma (rGBM). The trial is being conducted under an FDA Special Protocol Assessment (SPA), and VB-111 has obtained fast track and Orphan designations.